This study is looking at an oral drug called pacritinib for men with prostate cancer that has spread (metastatic) and is no longer responding to hormone therapy (castrate-resistant). You would be eligible if your cancer has progressed after previous treatments called androgen receptor signaling inhibitors (ARSI). To join, you'll need a recent biopsy showing a specific marker called STAT5 activation. The study will give pacritinib 200 mg twice daily. Researchers will measure how long you live without your cancer getting worse (progression-free survival) over six months to see if the treatment is successful. The study plans to enroll 32 participants.

Study design

This is a Phase 2, single-arm, open-label study, meaning all 32 participants will receive the same treatment, and everyone will know what treatment is being given.

What's involved

You would take pacritinib 200 mg by mouth twice daily. You will also need a biopsy of a metastatic site within 30 days of starting treatment.

Compensation

Not stated in the trial record.

Follow-up

The study measures progression-free survival at six months, suggesting follow-up for at least this period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.